Q1 2020 Conference Call

Tom Rönnlund, CEO Henrik Lundkvist, CFO

Lund, April 24, 2020



Safe Harbor Statement

This presentation contains certain forward-looking information that reflects Probi's present view of future events, as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. Given the risks associated with forward-looking statements, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Probi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

Probi does not make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. Probi does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.





1	Executive overview
2	Financial review
3	Outlook
4	Q&A



Stable start to 2020

- Organic sales growth of 11%
- Increased demand from existing and new customers
- Joint Venture established with Viva5



 Limited operational impact of Covid-19 pandemic in Q1



Impact on Probi by Covid-19 pandemic

- Increased demand for immune supporting products
- Maintaining full operational status at manufacturing facilities
- Extensive safety measures implemented including back-up plans for production and supply chain
- Longer term impact on consumer behavior unclear







VivaPro


- Strategic Joint Venture with US-based Viva5 Corporation
- Purpose to develop consumer-friendly probiotic products in new niche markets as beverages, bars, cereals and various powder products
- Based on spore-forming bacteria (*Bacillus* coagulans), more robust and resistant to elevated temperatures
- Ambition to strengthen the scientific body of evidence in the field of *Bacillus coagulans*
- 51% owned by Viva5 Corporation and 49% by Probi – option for Probi to acquire majority interest

VAPRO





Outperforming market growth but one-offs affecting margin






Healthy growth in Net Sales but weaker EBITDA-margin


Net sales

SEK m, sales growth in % (constant currency growth)



EBITDA

SEK m, EBITDA margin as % of Group net sales



Highlights in the quarter

- Net sales (organic) +11% compared to Q1 2019
- Increased interest for immune products in all markets
- Product mix and temporary disruptions in production had negative impact on gross margin
- Increased costs for Business development and R&D by SEK 5 m pushing EBITDA-margin down to 19%
- Expanded collaboration with large American customer will imply higher long-term sales volumes but also potentially increased quarter by quarter volatility in sales



Geographic market dynamics

Americas

- Current increased consumer demand in connection to Covid-19 pandemic
- Highest worldwide spending
 on supplements per capita
- High consumer quality awareness supports demand for premium probiotics

EMEA


- Large probiotic markets showing maturing growth while others (Turkey) indicate strong growth potential
- Functional Food relatively large share of probiotic market
- Market growth driven by supplements

APAC

- China is the dominant market and is estimated to show strongest growth ahead together with Australia
- Covid-19 related Chinese market shutdown beginning of 2020 affecting whole region, but signs of recovery from March
- Increasing disposable income and demand for premium probiotics



Net Sales and Gross Profit by region





Q1 2020 – Business highlights

- Covid-19 pandemic caused no major delays in customer deliveries. Significant increased interest in immune supporting products.
- VivaPro joint venture established.
- Strengthened partnership with one of our largest American customers.
 - Broader delivery commitment for Probi and future higher volumes
 - Potentially higher variation in sales and gross margins between quarters
- New members in executive management team.
 - Basudha Bhattarai-Johansson, Vice President HR
 - Shane Judge, Vice President Global Sales & Marketing
 - Hanne Risager-Romedahl, Vice President Research & Development










1	Executive overview
2	Financial review
3	Outlook
4	Q&A



Increased sales revenue but reduced EBITDA margin caused by one-offs

Probi sales bridge

SEK m, change in %



Condensed P&L

SEK m, change in %


	Q1 2020	Q1 2019	Change
Net sales	157.8	138.2	1 4%
EBITDA	29.9	28.2	▲ 6%
EBITDA margin	18.9%	20.4%	 -1.5pps
EBIT	11.0	11.3	▼ -3%
Net income	10.7	8.5	2 5%
EPS	0.94	0.75	2 5%



Increased net income due to stronger sales

Reconciliation of net income

SEK m




Key aspects

- Net income increased by SEK 2 m (+25%) compared to previous year
- Organic growth of sales SEK 15 m (11%), FX effect SEK 4 m
- Gross profit effected by disruption in production (SEK 3 m) and product mix (SEK 2 m) in total SEK 5 m
- Operating expenses increased by SEK 4 m mainly related to business development projects and R&D projects
- Exchange rate gain of SEK 3 m due to revaluation of cash & cash equivalents



Continued strong cash flow

Reconciliation of group liquidity



Key aspects

- Gross operating cash flow of MSEK 34 reflects robust business model
- Favourable working capital effect mainly due to decreased inventory
- Large tax payments in the quarter due to timing effects
- Capex mainly related to upgrade program in Redmond, USA
- Financing agreement due in July 2020 was terminated in the quarter as a result of strong cash flow
- Positive FX effect due to weaker SEK



15

Solid balance sheet with no external loans

Balance sheet Probi Group

SEK m, in % of total assets

Assets	31 Mar 2020	31 Dec 2019	Liabilities and equity	31 Mar 2020	31 Dec 2019
Intangibles (excl. GW)	503	482	Total equity	1,239	1,152
Goodwill	342	316			
PPE	115	107	Other non-current liabil.	52	52
Deferred tax assets	8	6	Non-current liabilities	52	52
Non-current assets	968	911	Borrowings	0	0
Inventories	77	79	Trade payables	37	38
Trade receivables	84	83	Other current liabilities	43	48
Other current assets	7	9	Current liabilities	80	86
Cash and cash equiv.	235	207	Total liabilities	133	137
Current assets	403	378			
Total assets	1,371	1,290	Liabilities and equity	1,371	1,290

Key aspects

- Net cash flow SEK 28 m
- Intangibles and Goodwill increased due to FX
- Total equity of SEK 1,239 m
- Equity ratio 90%
- Limited movements on remaining balance sheet items





1	Executive overview
2	Financial review
3	Outlook




Outlook geographic markets

	Americas	EMEA	APAC
Market sentiment:	Low digit growth	Stable growth	Recovery (driven by China)
Probi focus:	 Increase market share Growth in premium products Increase commercial resources, new market channels & market niches 	 Footprint in new important markets, Italy and Turkey Collaboration in partner projects 	 Identify right partners Grow with partners in Korea, Australia, India and China Return to growth
	Global annual growth in pro	obiotic supplements estimated	d to be 4% the coming 4 years



Probi's strategic focus areas





19



Financial calendar

2019 Annual General Meeting Interim report Q2, 2020 Interim report Q3, 2020 Year-end report, 2020 13 May 2020 17 Jul 2020 21 Oct 2020 9 Feb 2021

